Please feel free forward to your colleagues and share the news of our journal | Repairing the Parkinsonian Brain Volume 11, Issue s2 / 2021 Freely Available Online Editors: Anders Björklund, Bastiaan R. Bloem, Patrik Brundin, and Howard Federoff |  Indexed in: PubMed/MEDLINE Web of Science Scopus | Editorial Extract:
"Cell and gene therapy for brain diseases have been long in the making. Starting with the first speculative ideas and the initial exploratory trials in the 1980s and 1990s, followed by the major set-backs in the cell- and gene therapy fields at the turn of the century, and the renewed developments seen during the last decade. This revival of the cell- and gene-therapy field has been driven by the remarkable technical developments that have given us access to increasingly more powerful molecular and genetic tools and techniques, and opened up for more refined approaches to therapy for neurodegenerative diseases, and Parkinson's disease in particular. In this special issue, we highlight some of the current strategies that are pursued with the goal to restore lost function and replace what is lost in the PD brain, with a special emphasis on the challenges, regulatory and ethical, that are associated with the translation of advanced therapeutic approaches into pioneering clinical trials." Read about the special issue in the press release here & access all content below or here | Volume 11, Issue s2 / 2021 Open Access All content in this special issue is open access for you to read, download and share! | EDITORIAL
Repairing the Parkinsonian Brain
Björklund, Anders | Bloem, Bastiaan R. | Brundin, Patrik | Federoff, Howard PART I: Path to Clinical Trials for Advanced Therapies REVIEW ARTICLES
Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson’s Disease to the Clinic: The Investigator’s Perspective
Barker, Roger A. | Cutting, Emma V. | Daft, Danielle M. Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective
Tomishima, Mark | Kirkeby, Agnete Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Patient’s Perspective
Mathur, Soania | Stamford, Jon Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: An Analysis of Ethical Issues
Hug, Kristina PART II: Cell and Gene Therapies REVIEW ARTICLES
Dopamine Cell Therapy: From Cell Replacement to Circuitry Repair
Björklund, Anders | Parmar, Malin Evading the Immune System: Immune Modulation and Immune Matching in Cell Replacement Therapies for Parkinson’s Disease
Morizane, Asuka | Takahashi, Jun An Update on Gene Therapy Approaches for Parkinson’s Disease: Restoration of Dopaminergic Function
Van Laar, Amber D. | Van Laar, Victor S. | San Sebastian, Waldy | Merola, Aristide | Elder, J. Bradley | Lonser, Russell R. | Bankiewicz, Krystof S. Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations
Abeliovich, Asa | Hefti, Franz | Sevigny, Jeffrey Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies
Sandoval, Ivette M. | Marmion, David J. | Meyers, Kimberly T. | Manfredsson, Fredric P. Improved Delivery Methods for Gene Therapy and Cell Transplantation in Parkinson’s Disease
Larson, Paul S. PART III: Perspectives REVIEW ARTICLES
Next-Generation Gene Therapy for Parkinson’s Disease Using Engineered Viral Vectors
Björklund, Tomas | Davidsson, Marcus Endoplasmic Reticulum Stress Regulators: New Drug Targets for Parkinson’s Disease
Kovaleva, Vera | Saarma, Mart Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems
Jarrin, Sarah | Hakami, Abrar | Newland, Ben | Dowd, Eilís | Most Read JPD Articles in Q3 2021 Listing articles published only in 2020 and 2021 so you can read the most popular recent content | Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update – Open Access (Review Article in Vol.11, Iss.3, 2021)
McFarthing, Kevin | Rafaloff, Gary | Baptista, Marco A.S. | Wyse, Richard K. | Stott, Simon R. W. Effectiveness of Long-Term Physiotherapy in Parkinson’s Disease: A Systematic Review and Meta-Analysisc – Open Access (Research Article in pre-press, 2021)
Okada, Yohei | Ohtsuka, Hiroyuki | Kamata, Noriyuki | Yamamoto, Satoshi | Sawada, Makoto | Nakamura, Junji | Okamoto, Masayuki | Narita, Masaru | Nikaido, Yasutaka | et al. Parkinsonism as a Third Wave of the COVID-19 Pandemic? – Open Access (Research Article in Vol.10, Iss.4, 2020)
Beauchamp, Leah C. | Finkelstein, David I. | Bush, Ashley I. | Evans, Andrew H. | Barnham, Kevin J. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective – Open Access (Review Article in Vol.11, Iss.1, 2021)
Stephenson, Diane | Badawy, Reham | Mathur, Soania | Tome, Maria | Rochester, Lynn COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the Tunnel? – Open Access (Article Commentary in Vol.11, Iss.1, 2021) (View Press Release)
Bloem, Bastiaan R. | Trenkwalder, Claudia | Sanchez-Ferro, Alvaro | Kalia, Lorraine V. | Alcalay, Roy | Chiang, Han-Lin | Kang, Un Jung | Goetz, Christopher | Brundin, Patrik | Papa, Stella M. | World Parkinson Coalition View Recent Blog Post A recent blog post on the World Parkinson Coalition (WPC) website has a clinical science focus and is written by Heidi McBride, PhD, who is a Professor at McGill University in the Department of Neurology and Neurosurgery located within the Montreal Neurological Institute. | VIEW BLOG A Personal and Scientific Journal into Parkinson's Disease: The Promise and Power of Collaboration Extract: "My entry into Parkinson’s research coincided with a series of studies in the mid-2000s showing that at least two specific PD-related proteins PINK1 and Parkin were linked to mitochondrial dynamics and quality control in fly models of disease. This prompted a team of Parkinson’s scientists in Montreal and Ottawa to ask me to join them in a collaborative grant from Brain Canada to explore the mitochondrial contribution to PD. As a mitochondrial cell biologist my team had discovered that mitochondria could shed vesicles, and we knew these vesicles could target damaged mitochondrial proteins to the late endosome/lysosome. Dr. Ted Fon at the Montreal Neurological Institute had shown earlier that Parkin could regulate vesicle transport from the cell surface, so we began to work together to test whether PINK1 and Parkin might regulate mitochondrial vesicle transport. While the field exploded in 2008 with Richard Youle’s discovery that PINK1 and Parkin can mediate mitophagy (the digestion of entire mitochondrial organelles), we continued our work into the mechanisms and function of more targeted mitochondrial protein degradation. With Ted we eventually published a number of papers outlining this pathway and the contribution of PINK and Parkin to the removal of selective mitochondrial proteins for degradation." | If you know any colleagues and fellow researchers who are not signed up to receive the newsletter, we invite you to share this mailing with them. They can sign up at: tiny.cc/JPDsignup Also, if you are not already, be sure to follow us on Twitter and find us on Facebook for news related to JPD and PD research. Be part of the discussion! | You are receiving this mailing as you are signed up to receive news from JPD.
You can unsubscibe or alter your preferences at any time by clicking the links below. | |
